News Releases
Dec 5, 2011:
iCo Therapeutics Announces Execution of Equity Line Facility Agreement
Nov 18, 2011:
iCo Therapeutics Announces Third Quarter 2011 Financial Results
Nov 2, 2011:
iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement
Oct 24, 2011:
iCo Therapeutics Oral Amphotericin B Delivery System to be Presented at AAPS
Oct 20, 2011:
iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit
Sep 27, 2011:
iCo Therapeutics Grants Options to Directors, Officers and Employees
Sep 26, 2011:
iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
Sep 13, 2011:
iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference
Aug 29, 2011:
iCo Therapeutics Announces Second Quarter 2011 Financial Results
Aug 15, 2011:
iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone
Jul 23, 2011:
iCo Therapeutics Announces Resignation of John Clement, Chief Technology and Development Officer and Director
Jul 19, 2011:
iCo Therapeutics Engages The Equicom Group
Jul 12, 2011:
iCo Therapeutics CMO to Present at The Drug Repositioning Conference
Jun 29, 2011:
iCo Therapeutics Announces First Quarter 2011 Financial Results
Jun 24, 2011:
iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals
May 31, 2011:
iCo Therapeutics CEO to Present & Participate in Panel at BioFinance 2011
May 13, 2011:
iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance
Apr 29, 2011:
iCo Therapeutics Announces Year-End 2010 Financial Results
Apr 14, 2011:
iCo Therapeutics Inc. Secures $10 Million Equity Line Facility
Feb 23, 2011:
iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011
Feb 22, 2011:
iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing
Copyright 2010 ICO Therapeutics | Disclaimer